The role of gut microbiome in chemoresistance property development in colorectal cancer tissue and its novel therapeutic strategies

JOURNAL OF CHEMOTHERAPY · Published 2026-04-16 · DOI 10.1080/1120009x.2026.2653339

Authors being retrieved — see the publisher record. https://doi.org/10.1080/1120009x.2026.2653339

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• The impact of low-volume hydration on kidney function in low-dose cisplatin therapy for biliary tract cancer: a multicentre retrospective cohort study · JOURNAL OF CHEMOTHERAPY · 2026 · Same journal
• Pharmacokinetic/pharmacodynamic optimization of antimicrobial therapy in neutropenic sepsis: a comprehensive review · JOURNAL OF CHEMOTHERAPY · 2026 · Same journal
• Successful remdesivir treatment of coronavirus OC43 pneumonia in a lung transplant recipient · JOURNAL OF CHEMOTHERAPY · 2025 · Same journal
• A Phase 1 study of abemaciclib plus abiraterone in Japanese patients with metastatic castration-resistant prostate cancer · JOURNAL OF CHEMOTHERAPY · 2025 · Same journal
• A 1:1:1 propensity score matching design to account for center-specific antimicrobial treatment or prophylaxis in observational studies: the case of the POSACOVID study · JOURNAL OF CHEMOTHERAPY · 2026 · Same journal
• Striking effectiveness of siltuximab-based treatment in refractory idiopathic multicentric Castleman disease resembling IgG4-related disease · JOURNAL OF CHEMOTHERAPY · 2025 · Same journal
• The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study · JOURNAL OF CHEMOTHERAPY · 2025 · Same journal
• Influencing factors of acute severe to very severe peripheral neuropathy induced by albumin-bound paclitaxel · JOURNAL OF CHEMOTHERAPY · 2025 · Same journal
• Oritavancin as sequential therapy for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis: a case report · JOURNAL OF CHEMOTHERAPY · 2026 · Same journal
• Furmonertinib activity in NSCLC Harbouring EGFR L858R and ERBB2 S310F co-mutations: a case report with literature review · JOURNAL OF CHEMOTHERAPY · 2025 · Same journal